Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer
The overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second and third line settings.
Checked against the public recordLast updated May 12, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- University of Wisconsin, Madison
- Interventions being studied
- Drug: Docetaxel; Drug: Suramin; Drug: Docetaxel
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Pathologically proven diagnosis of non-small cell lung cancer * Documented disease progression after first-line chemotherapy for non-small cell lung cancer * Stable and treated CNS metastasis is allowed * Radiation must be completed at least 2 weeks prior to starting protocol treatment * Major surgery must be completed at least 4 weeks prior to starting protocol treatment * ECOG performance status 0-2 * Sexually active patients must use adequate contraception * Adequate bone marrow function * Adequate renal function * Adequate liver function Exclusion Criteria: * Severe hypersensitivity reaction to docetaxel * Pre-existing grade 3 or 4 neuropathy * Women who are pregnant or breastfeeding * Uncontrolled intercurrent illness * Receipt of 3 or more prior chemotherapy regimens
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Wisconsin Carbone Comprehensive Cancer CenterMadison, Wisconsin
- Medical College of WisconsinMilwaukee, Wisconsin
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 12, 2020. Always confirm current availability with the study team.